Could Juno Therapeutics Inc See a Reversal After Today’s Strong Options Activity?

 Could Juno Therapeutics Inc See a Reversal After Today's Strong Options Activity?

In today’s session Juno Therapeutics Inc (JUNO) registered an unusually high (420) contracts volume of call trades. Someone, most probably a professional was a very active buyer of the December, 2016 call, expecting serious JUNO increase. With 420 contracts traded and 1554 open interest for the Dec, 16 contract, it seems this is a quite bullish bet. The option with symbol: JUNO161216C00027500 closed last at: $0.65 or 83.8% down. About 1.33M shares traded hands. Juno Therapeutics Inc (NASDAQ:JUNO) has declined 49.28% since April 22, 2016 and is downtrending. It has underperformed by 54.69% the S&P500.

Analysts await Juno Therapeutics Inc (NASDAQ:JUNO) to report earnings on March, 6. They expect $-0.66 EPS, down 22.22% or $0.12 from last year’s $-0.54 per share. After $-0.58 actual EPS reported by Juno Therapeutics Inc for the previous quarter, Wall Street now forecasts 13.79% negative EPS growth.

Juno Therapeutics Inc (NASDAQ:JUNO) Ratings Coverage

Out of 10 analysts covering Juno Therapeutics Inc (NASDAQ:JUNO), 5 rate it a “Buy”, 0 “Sell”, while 5 “Hold”. This means 50% are positive. $73 is the highest target while $25 is the lowest. The $42.82 average target is 93.14% above today’s ($22.17) stock price. Juno Therapeutics Inc has been the topic of 22 analyst reports since July 22, 2015 according to StockzIntelligence Inc. The firm has “Buy” rating by Suntrust Robinson given on Friday, January 29. The firm earned “Outperform” rating on Friday, July 8 by FBR Capital. Barclays Capital initiated the shares of JUNO in a report on Wednesday, July 6 with “Equal-Weight” rating. Maxim Group maintained the stock with “Buy” rating in Wednesday, November 23 report. Standpoint Research initiated it with “Buy” rating and $47.0 target price in Monday, August 24 report. Standpoint Research upgraded the shares of JUNO in a report on Tuesday, December 15 to “Buy” rating. JP Morgan downgraded it to “Neutral” rating and $39 target price in Friday, July 8 report. The stock of Juno Therapeutics Inc (NASDAQ:JUNO) earned “Buy” rating by Citigroup on Thursday, February 25. The rating was initiated by Goldman Sachs on Wednesday, November 18 with “Neutral”. As per Wednesday, July 22, the company rating was initiated by Northland Capital.

According to Zacks Investment Research, “Juno Therapeutics, Inc. is a biopharmaceutical company. The Company develops cellular immunotherapies based on two platforms – Chimeric Antigen Receptors (CARs) and T Cell Receptors (TCRs) technologies. Its clinical CD19 product candidates include JCAR015 that is in Phase I clinical trials for adult patients with relapsed/refractory B cell acute lymphoblastic leukemia (r/r ALL); JCAR017, which is in Phase I/II trials for pediatric patients with r/r ALL whose cancer has recurred after a bone marrow transplant; and JCAR014 that is in Phase I/II trials to treat various B cell malignancies in patients relapsed or refractory to standard therapies. Juno Therapeutics, Inc. is headquartered in Seattle, Washington.”

Insitutional Activity: The institutional sentiment increased to 1.4 in 2016 Q2. Its up 0.06, from 1.34 in 2016Q1. The ratio increased, as 25 funds sold all Juno Therapeutics Inc shares owned while 36 reduced positions. 23 funds bought stakes while 59 increased positions. They now own 44.56 million shares or 5.68% more from 42.17 million shares in 2016Q1.
The Maryland-based Profund Advsr Ltd has invested 0.07% in Juno Therapeutics Inc (NASDAQ:JUNO). Moreover, Us Savings Bank De has 0.01% invested in Juno Therapeutics Inc (NASDAQ:JUNO) for 90,900 shares. Perceptive Advsr Limited Liability owns 1,113 shares or 0% of their US portfolio. Bnp Paribas Arbitrage, a New York-based fund reported 14,678 shares. Moreover, Panagora Asset Inc has 0% invested in Juno Therapeutics Inc (NASDAQ:JUNO) for 2,710 shares. Barclays Public Ltd reported 25,347 shares or 0% of all its holdings. Moreover, Checchi Capital Advisers Ltd Liability Co has 0% invested in Juno Therapeutics Inc (NASDAQ:JUNO) for 162 shares. Brighton Jones Ltd Liability accumulated 6,379 shares or 0.04% of the stock. Winfield Assocs has 20 shares for 0% of their US portfolio. Tower Cap Ltd Liability (Trc) has 70 shares for 0% of their US portfolio. Artal Gp Sa has 0.16% invested in the company for 200,000 shares. Baker Bros Advsr Ltd Partnership last reported 0.03% of its portfolio in the stock. Federated Investors Inc Pa holds 27,614 shares or 0% of its portfolio. Susquehanna Int Grp Llp has 101,172 shares for 0% of their US portfolio. Allianz Asset Mgmt Ag last reported 0% of its portfolio in the stock.

Juno Therapeutics, Inc. is a biopharmaceutical firm focused on re-engaging the body’s immune system to revolutionize the treatment of cancer. The company has a market cap of $1.77 billion. The Firm is developing cell cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells. It currently has negative earnings. Juno’s product candidates, JCAR015, JCAR017 and JCAR014, utilize CAR technology to target CD19, a protein expressed on the surface of various B cell leukemias and lymphomas.

JUNO Company Profile

Juno Therapeutics, Inc. (Juno), incorporated on August 5, 2013, is a biopharmaceutical firm focused on re-engaging the body’s immune system to revolutionize the treatment of cancer. The Firm is developing cell cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells. Juno’s product candidates, JCAR015, JCAR017 and JCAR014, utilize CAR technology to target CD19, a protein expressed on the surface of various B cell leukemias and lymphomas. The Company’s CAR and TCR technologies alter T cells ex vivo, or outside the body. In addition, the Company holds license to vipadenant, a small molecule adenosine A2a (A2a) receptor antagonist that has the potential to disrupt important immunosuppressive pathways in the tumor microenvironment in certain cancers.

More recent Juno Therapeutics Inc (NASDAQ:JUNO) news were published by: Fool.com which released: “Why Juno Therapeutics Inc Plummeted Today” on November 23, 2016. Also Marketwatch.com published the news titled: “UPDATE: Juno Therapeutics plummets 30% in pre-market trade after two patient …” on November 23, 2016. Fool.com‘s news article titled: “Better Buy: Ziopharm Oncology, Inc. vs. Juno Therapeutics” with publication date: November 03, 2016 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment